[Home ] [Archive]    
:: Home :: About Journal :: Registration :: Article Submission :: Contact us :: Site Map ::
:: Volume 14, Issue 3 (September-2022 2022) ::
IJBC 2022, 14(3): 1-10 Back to browse issues page
The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial
Mohammadreza Bordbar, Gholamreza Fathpour *, Seyed Mohsen Dehghani, Sezaneh Haghpanah, Hossein Molavi Vardanjani, Mohammadreza Fattahi, Mahdi Shahriari, Nader Shakibazad
Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:   (50 Views)
Background: This study aimed to investigate the protective role of deferoxamine (DFO) in the prevention of doxorubicin (DOX)-induced hepatic fibrosis in children.
Methods: In this prospective randomized controlled trial, 61 treatment-naïve children (2-18 years) with different types of cancer who referred to a tertiary teaching hospital in the South of Iran were enrolled. They were randomly assigned to 3 groups; group 1 (control, n=21), group 2 (DFO 10 times DOX dose, n=20), group 3 (DFO 50mg/kg, n=20). DFO was administered as an 8-hour continuous intravenous infusion during and after DOX infusion in each chemotherapy cycle. Non-invasive serum markers of liver fibrosis, including AST-to-platelet ratio index (APRI), Fibrosis-4 (FIB-4) score and Fibro Test were measured in each individual. Besides, hepatic Fibro Scan was used after the last course of chemotherapy to estimate the fibrosis degree.
Results: Alanine aminotransferase was mildly increased after treatment compared to before treatment. The treatment with DFO 10 times DOX dose was associated with a significant decline in post-treatment APRI (adjusted odds ratio 0.17; 95% confidence interval 0.03- 0.84. P-value=0.015). The METAVIR fibro scores were in the F0-F1 zone in all participants, and the results were comparable in study groups. No adverse drug effects were reported in the treatment groups.
Conclusion: DOX may not lead to severe liver fibrosis if the maximum cumulative dose allowed is not exceeded. DFO at the dose of 10 times of DOX dose may have a potential protective role against liver fibrosis. More studies with longer follow-up are needed to further assess this issue.
Keywords: Deferoxamine, Doxorubicin, Hepatic fibrosis, Children
Full-Text [PDF 491 kb]   (44 Downloads)    
: Research | Subject: Pediatric Hematology & Oncology
Received: 2021/10/12 | Accepted: 2022/07/17 | Published: 2022/09/19
* Corresponding Author Address: Hematology Research center, Shiraz University of Medical Sciences, Shiraz, Iran
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bordbar M, Fathpour G, Dehghani S M, Haghpanah S, Molavi Vardanjani H, Fattahi M, et al . The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial. IJBC 2022; 14 (3) :1-10
URL: http://ijbc.ir/article-1-1191-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 3 (September-2022 2022) Back to browse issues page
مجله ی خون و سرطان ایران Iranian Journal of Blood and Cancer
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4509